TWI826254B - Whitening composition and use thereof - Google Patents
Whitening composition and use thereof Download PDFInfo
- Publication number
- TWI826254B TWI826254B TW112104281A TW112104281A TWI826254B TW I826254 B TWI826254 B TW I826254B TW 112104281 A TW112104281 A TW 112104281A TW 112104281 A TW112104281 A TW 112104281A TW I826254 B TWI826254 B TW I826254B
- Authority
- TW
- Taiwan
- Prior art keywords
- extract
- whitening composition
- coral
- andrographis paniculata
- rosemary
- Prior art date
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 98
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- 239000000284 extract Substances 0.000 claims abstract description 136
- 244000118350 Andrographis paniculata Species 0.000 claims abstract description 81
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 15
- 239000011780 sodium chloride Substances 0.000 claims abstract description 8
- 244000132059 Carica parviflora Species 0.000 claims description 68
- 235000014653 Carica parviflora Nutrition 0.000 claims description 68
- 244000025254 Cannabis sativa Species 0.000 claims description 60
- 229940092258 rosemary extract Drugs 0.000 claims description 58
- 235000020748 rosemary extract Nutrition 0.000 claims description 58
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims description 58
- 238000000605 extraction Methods 0.000 claims description 43
- 238000002360 preparation method Methods 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 210000002752 melanocyte Anatomy 0.000 claims description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 14
- 239000002953 phosphate buffered saline Substances 0.000 claims description 14
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 7
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 3
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 241001529742 Rosmarinus Species 0.000 abstract description 24
- 240000004274 Sarcandra glabra Species 0.000 abstract description 4
- 235000010842 Sarcandra glabra Nutrition 0.000 abstract description 4
- 241000746375 Andrographis Species 0.000 abstract description 3
- 239000008363 phosphate buffer Substances 0.000 abstract description 2
- 102000003425 Tyrosinase Human genes 0.000 description 37
- 108060008724 Tyrosinase Proteins 0.000 description 37
- 230000000694 effects Effects 0.000 description 23
- 238000012360 testing method Methods 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 10
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 9
- 239000000287 crude extract Substances 0.000 description 9
- 108010051081 dopachrome isomerase Proteins 0.000 description 9
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 8
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000036564 melanin content Effects 0.000 description 7
- 230000008099 melanin synthesis Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 3
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 3
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 2
- 241000207965 Acanthaceae Species 0.000 description 1
- 241000758719 Chloranthaceae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 241000736026 Sarcandra Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Images
Abstract
Description
本發明係關於一種組合物,尤其是一種美白組合物。本發明另關於該美白組合物的用途。The present invention relates to a composition, especially a whitening composition. The present invention also relates to the use of the whitening composition.
愛美是人的天性,古今中外皆如此。然而,對於東方人來說,一白遮三醜的觀念引響深遠,導致東方人愛美白更勝於他人。因此,美白保養品的產值在市場上居高不下,也促成許多新原料的開發。It is human nature to love beauty, and this is true at all times and in all countries. However, for Orientals, the concept of whitening to cover up three ugliness has far-reaching influence, which leads Orientals to love whitening more than others. Therefore, the output value of whitening and skin care products remains high in the market, which has also led to the development of many new raw materials.
人體照射到陽光會變黑乃是人體的防禦機制。在經過一系列的生化反應後,黑色素會作為代謝產物而產生,而這也是導致皮膚變黑的主要物質。簡言之,黑色素細胞中含有酪胺酸(tyrosin),當黑色素細胞中的酪胺酸酶(tyrosinase)被活化後,會促進酪胺酸轉化為多巴(3,4-dihydroxyphenylalanine,簡稱為DOPA),而多巴會再進一步轉化為多巴醌(dopaquinone),最終形成真黑色素(eumelanin)、類黑色素(pheomelanin)等黑色素(melanin)。因此,這一系列的生化反應可歸因於黑色素細胞中的酪胺酸酶的反應。The human body turns black when exposed to sunlight, which is the body's defense mechanism. After a series of biochemical reactions, melanin is produced as a metabolic product, which is also the main substance that causes skin darkening. In short, melanocytes contain tyrosin. When tyrosinase in melanocytes is activated, it will promote the conversion of tyrosine into dopa (3,4-dihydroxyphenylalanine, referred to as DOPA). ), and dopa will be further converted into dopaquinone, eventually forming melanin such as eumelanin and pheomelanin. Therefore, this series of biochemical reactions can be attributed to the reaction of tyrosinase in melanocytes.
換言之,若能找出方法抑制黑色素細胞中的酪胺酸酶的活性,便能夠有效減少黑色素的產生。因此,許多研究開發者專注於從陸地植物或海洋生物中尋找能夠美白、淡化膚色,以及抑制黑色素生成的天然成分,期許能開發功效更好的有效成分。In other words, if we can find a way to inhibit the activity of tyrosinase in melanocytes, we can effectively reduce the production of melanin. Therefore, many researchers and developers focus on finding natural ingredients from land plants or marine organisms that can whiten, lighten skin tone, and inhibit melanin production, hoping to develop effective ingredients with better efficacy.
為解決上述問題,本發明的主要目的在於一種美白組合物,以有效抑制黑色素細胞中酪胺酸酶的活性者。In order to solve the above problems, the main object of the present invention is a whitening composition that can effectively inhibit the activity of tyrosinase in melanocytes.
本發明的次一目的是提供美白組合物的用途,係將本發明的美白組合物應用於製備美白製劑者。A secondary object of the present invention is to provide the use of a whitening composition, which is to apply the whitening composition of the present invention to prepare whitening preparations.
本發明全文所記載的元件及構件使用「一」或「一個」之量詞,僅是為了方便使用且提供本發明範圍的通常意義;於本發明中應被解讀為包括一個或至少一個,且單一的概念也包括複數的情況,除非其明顯意指其他意思。The use of the quantifier "a" or "an" in the elements and components described throughout the present invention is only for convenience of use and to provide a common sense of the scope of the present invention; in the present invention, it should be interpreted as including one or at least one, and single The concept of also includes the plural unless it is obvious that something else is meant.
本發明的美白組合物,可以包含:一草珊瑚萃取物;一迷迭香萃取物;及一穿心蓮萃取物,該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物係能夠以一磷酸鹽緩衝生理鹽水溶液作為萃取劑,於介於1~1.2 Kgf/cm 2之間的壓力及介於121~135℃之間的溫度下,分別萃取一草珊瑚樣品、一迷迭香樣品及一穿心蓮樣品所獲得。 The whitening composition of the present invention may include: a herbaceous coral extract; a rosemary extract; and an Andrographis paniculata extract, and the herbaceous coral extract, the rosemary extract and the Andrographis paniculata extract can be combined with one Phosphate buffered saline solution was used as the extraction agent, and a sample of Coral Coral, a sample of Rosemary and A sample of Andrographis paniculata was obtained.
據此,本發明的美白組合物,藉由該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物的組成,不僅可以有效抑制酪胺酸酶的活性,更可以阻斷與黑色素生成有關的訊息傳遞路徑,進而能夠減少黑色素的生成,因此,該美白組合物可以應用於製備美白製劑,供投予一所需個體,以抑制該所需個體的黑色素細胞中的黑色素的生成,為本發明之功效。Accordingly, the whitening composition of the present invention, composed of the grass coral extract, the rosemary extract and the Andrographis paniculata extract, can not only effectively inhibit the activity of tyrosinase, but also block the production of melanin. Relevant message transmission pathways can further reduce the production of melanin. Therefore, the whitening composition can be used to prepare whitening preparations for administration to a desired individual to inhibit the production of melanin in the melanocytes of the desired individual. Efficacy of the present invention.
本發明的美白組合物,其中,該磷酸鹽緩衝生理鹽水溶液可以包含濃度介於0.12~0.14 M之間的氯化鈉及濃度介於0.008~0.012 M之間的磷酸二氫鈉,且該磷酸鹽緩衝生理鹽水溶液的pH值可以為中性。如此,以此成分的磷酸鹽緩衝生理鹽水作為萃取劑所得到的草珊瑚萃取物、迷迭香萃取物及穿心蓮萃取物,對酪胺酸酶具有較佳的抑制活性。The whitening composition of the present invention, wherein the phosphate buffered physiological saline solution can include sodium chloride with a concentration between 0.12 and 0.14 M and sodium dihydrogen phosphate with a concentration between 0.008 and 0.012 M, and the phosphoric acid The pH of the salt-buffered saline solution may be neutral. In this way, the grass coral extract, rosemary extract and Andrographis paniculata extract obtained by using phosphate buffered saline as the extraction agent have better inhibitory activity against tyrosinase.
本發明的美白組合物,其中,可以在分別獲得該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物之後,再混合該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物,以形成該美白組合物。如此,藉由分別萃取獲得該草珊瑚樣品、該迷迭香樣品及該穿心蓮樣品,可以依照該草珊瑚樣品、該迷迭香樣品及該穿心蓮樣品的狀態分別調整萃取條件,從而提高所獲得的草珊瑚萃取物、迷迭香萃取物及穿心蓮萃取物的品質。In the whitening composition of the present invention, after obtaining the Herba Coral extract, the Rosemary extract and the Andrographis paniculata extract respectively, the Herba Coral extract, the Rosemary extract and the Andrographis paniculata extract can be mixed. to form the whitening composition. In this way, by separately extracting the grass coral sample, the rosemary sample and the andrographis paniculata sample, the extraction conditions can be adjusted respectively according to the status of the grass coral sample, the rosemary sample and the andrographis paniculata sample, thereby improving the obtained Quality of Grass Coral Extract, Rosemary Extract and Andrographis Paniculata Extract.
本發明的美白組合物,其中,該美白組合物可以包含以重量百分比計為15~55%的草珊瑚萃取物、30~55%的迷迭香萃取物及15~55%的穿心蓮萃取物;較佳可以包含以重量百分比計為33.3%的草珊瑚萃取物、50%的迷迭香萃取物及16.7%的穿心蓮萃取物。如此,藉由該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物的特定比例,使該美白組合物具有較佳的酪胺酸酶的抑制活性。The whitening composition of the present invention, wherein the whitening composition may comprise 15 to 55% of Coral grass extract, 30 to 55% of Rosemary extract and 15 to 55% of Andrographis paniculata extract by weight percentage; Preferably, it may include 33.3% of Coral grass extract, 50% of Rosemary extract and 16.7% of Andrographis paniculata extract by weight. In this way, the whitening composition has better tyrosinase inhibitory activity through the specific ratio of the grass coral extract, the rosemary extract and the Andrographis paniculata extract.
本發明的美白組合物的用途,係應用於製備美白製劑,其中,該美白組合物係為如前述之美白組合物,且供投予一所需個體,以抑制該所需個體的黑色素細胞中的黑色素的生成。The use of the whitening composition of the present invention is applied to the preparation of whitening preparations, wherein the whitening composition is the aforementioned whitening composition, and is administered to a desired individual to inhibit the production of melanocytes in the desired individual. The production of melanin.
據此,本發明的美白組合物的用途,藉由使用如前述的美白組合物,進而能夠達成有效抑制黑色素的生成之功效。Accordingly, the use of the whitening composition of the present invention can further achieve the effect of effectively inhibiting the production of melanin by using the aforementioned whitening composition.
本發明的美白組合物的用途,其中,該美白組合物係能夠以塗抹或噴灑等方式投予該所需個體。如此,藉由所選用的投予方式,使該美白組合物可以便利地投予該所需個體。The use of the whitening composition of the present invention, wherein the whitening composition can be administered to the desired individual by smearing or spraying. In this way, the whitening composition can be conveniently administered to the desired individual through the selected administration method.
本發明的美白組合物的用途,其中,該美白組合物係能夠以200~500 μg/cm 2的劑量施予於該所需個體。如此,藉由所選用的劑量,使該美白組合物可以發揮較佳的美白效果。 The use of the whitening composition of the present invention, wherein the whitening composition can be administered to the desired individual at a dose of 200 to 500 μg/cm 2 . In this way, by selecting the dosage, the whitening composition can exert a better whitening effect.
為讓本發明之上述及其他目的、特徵及優點能更明顯易懂,下文特舉本發明之較佳實施例,並配合所附圖式作詳細說明。In order to make the above and other objects, features and advantages of the present invention more obvious and understandable, preferred embodiments of the present invention are illustrated in detail below and described in detail with reference to the accompanying drawings.
本發明之一實施例的美白組合物,係可以包含:一草珊瑚萃取物、一迷迭香萃取物及一穿心蓮萃取物,以藉由該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物的共同作用,有效抑制酪胺酸酶的活性,並可以阻斷與黑色素合成有關的訊息傳遞路徑(signal transduction pathway),進而能夠減少黑色素的生成,降低黑色素細胞中的黑色素含量。The whitening composition according to an embodiment of the present invention may include: a Coral Coral extract, a rosemary extract and an Andrographis paniculata extract, so that through the Coral Coral extract, the Rosemary extract and the The combined effect of Andrographis paniculata extract can effectively inhibit the activity of tyrosinase and block the signal transduction pathway related to melanin synthesis, thereby reducing the production of melanin and reducing the melanin content in melanocytes.
詳而言之,用以製造獲得該美白組合物的方法係可以如第1圖所示,包含:一草珊瑚萃取物製備步驟S1、一迷迭香萃取物製備步驟S2、一穿心蓮萃取物製備步驟S3,以分別製備該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物。且在分別獲得該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物之後,工者可以再藉由一調製步驟S4,混合該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物,進而獲得該美白組合物。In detail, the method for manufacturing the whitening composition can be as shown in Figure 1, including: a step S1 of preparing a herbaceous extract, a step S2 of preparing a rosemary extract, and a step S2 of preparing an Andrographis paniculata extract. Step S3, to prepare the Coral grass extract, the rosemary extract and the Andrographis paniculata extract respectively. And after obtaining the Herba Coral extract, the Rosemary extract and the Andrographis paniculata extract respectively, the worker can then mix the Herba Coral extract, the rosemary extract and the Andrographis paniculata through a preparation step S4. extract to obtain the whitening composition.
於該草珊瑚萃取物製備步驟S1中,工者係以一萃取劑萃取一草珊瑚樣品所得。該草珊瑚樣品可以為來金粟蘭科(Chloranthaceae)珊瑚屬( Sarcandra)的植物[即,草珊瑚( Sarcandra glabra)],較佳可以為前述植物的全株。舉例而言,該草珊瑚萃取物係可以藉由包含以下步驟之方法所製得:一樣品提供次步驟S11、一萃取次步驟S12、一濃縮次步驟S13。 In the preparation step S1 of the grass coral extract, the worker extracts a grass coral sample with an extraction agent. The grass coral sample can be a plant of the genus Sarcandra in the Chloranthaceae family (ie, Sarcandra glabra ), and preferably can be the whole plant of the aforementioned plant. For example, the grass coral extract can be prepared by a method including the following steps: providing a sample as a step S11, an extraction as a step S12, and a concentration as a step S13.
於該樣品提供次步驟S11中,工者係可以在取得該草珊瑚樣品之後直接進行該萃取次步驟S12,或者亦可以在進行該萃取次步驟S12之前,預先將該草珊瑚樣品進行乾燥,例如乾燥使該草珊瑚樣品的含水量降低至3~10%;此外,該草珊瑚樣品亦可以預先進行粉碎,例如使該草珊瑚樣品的粒徑可以介於5~20 nm之間,以增加於該萃取次步驟S12中所使用之萃取劑的接觸表面積,藉此提升後續之萃取效率。In the sample providing sub-step S11, the worker can directly perform the extraction sub-step S12 after obtaining the grass coral sample, or the worker can pre-dry the grass coral sample before performing the extraction sub-step S12, for example Drying reduces the water content of the grass coral sample to 3-10%; in addition, the grass coral sample can also be crushed in advance, for example, the particle size of the grass coral sample can be between 5-20 nm to increase the The contact surface area of the extraction agent used in the extraction sub-step S12 thereby improves the subsequent extraction efficiency.
於該萃取次步驟S12中,工者係能夠以一磷酸鹽緩衝生理鹽水(phosphate buffer saline,簡稱PBS)溶液作為萃取劑,以萃取該草珊瑚樣品。舉例而言,該磷酸鹽緩衝生理鹽水溶液係可以包含氯化鈉(NaCl,sodium chloride)及磷酸二氫鈉(NaH 2PO 4,sodium dihydrogen phosphate)的一水溶液,且該水溶液的酸鹼值大抵為中性。例如該磷酸鹽緩衝生理鹽水溶液可以包含濃度介於0.12~0.14 M之間的氯化鈉及濃度介於0.008~0.012 M之間的磷酸二氫鈉,較佳可以包含濃度為0.13 M的氯化鈉及濃度為0.01 M的磷酸二氫鈉,且該磷酸鹽緩衝生理鹽水溶液的酸鹼值為7.0。 In the extraction sub-step S12, the worker can use a phosphate buffer saline (PBS) solution as an extraction agent to extract the grass coral sample. For example, the phosphate buffered saline solution may include an aqueous solution of sodium chloride (NaCl, sodium chloride) and sodium dihydrogen phosphate (NaH 2 PO 4 , sodium dihydrogen phosphate), and the pH value of the aqueous solution is approximately For neutral. For example, the phosphate buffered saline solution may contain sodium chloride at a concentration of 0.12-0.14 M and sodium dihydrogen phosphate at a concentration of 0.008-0.012 M. Preferably, it may contain chloride at a concentration of 0.13 M. Sodium and sodium dihydrogen phosphate with a concentration of 0.01 M, and the pH value of the phosphate buffered saline solution is 7.0.
於本實施例中,每200克的草珊瑚樣品係能夠混合200毫升的該萃取劑,以得一混合物,接著於介於1~1.2 Kgf/cm 2之間(例如1.033 Kgf/cm 2)的壓力、介於121~135℃之間(例如127℃)的溫度下進行萃取,萃取的時間可以介於20~30分鐘之間(例如30分鐘),使該草珊瑚樣品所富含之活性成分可以完整溶出於該萃取劑,如此即可以獲得一草珊瑚粗萃液。 In this embodiment, 200 ml of the extraction agent can be mixed with every 200 grams of grass coral sample to obtain a mixture, and then the mixture is mixed with a mixture of 1 to 1.2 Kgf/cm 2 (for example, 1.033 Kgf/cm 2 ). Extraction is performed under pressure and at a temperature between 121 and 135°C (for example, 127°C), and the extraction time can be between 20 and 30 minutes (for example, 30 minutes), so that the grass coral sample is rich in active ingredients. It can be completely dissolved in the extractant, so that a crude coral extract can be obtained.
於該濃縮次步驟S13中,工者係可以在取得該草珊瑚粗萃液之後,將該草珊瑚粗萃液進行冷凍乾燥,以獲得該草珊瑚萃取物,藉由此一程序,係可以使該草珊瑚萃取物之活性成分更加濃縮,是以僅需使用少量之該草珊瑚萃取物即可以發揮最佳效果。於本實施例中,係使用高速離心機,以12,000 rpm的轉速離心20分鐘,使該草珊瑚粗萃液中的殘渣沉澱之後,去除該些殘渣,續於介於-50~-80℃之間的溫度下將所得的上清液冷凍乾燥以獲得乾燥粉體,即可以獲得該草珊瑚萃取物。In the concentration sub-step S13, the worker can freeze-dry the crude coral extract after obtaining the crude coral extract to obtain the coral grass extract. Through this procedure, the system can The active ingredients of the grass coral extract are more concentrated, so only a small amount of the grass coral extract is needed to achieve the best effect. In this example, a high-speed centrifuge was used to centrifuge at 12,000 rpm for 20 minutes to precipitate the residues in the rough coral extract, and then the residues were removed, and then the mixture was centrifuged at a temperature between -50 and -80°C. The obtained supernatant liquid is freeze-dried at a temperature between 100% and 200% to obtain dry powder, and the grass coral extract can be obtained.
又,於該迷迭香萃取物製備步驟S2及該穿心蓮萃取物製備步驟S3中,工者係分別以該萃取劑萃取一迷迭香樣品及一穿心蓮樣品所得。該迷迭香樣品可以為來唇形科(Lamiaceae)迷迭香屬( Rosmarinus)的植物[即,迷迭香( Rosmarinus officinalis)],較佳可以為前述植物的全株,且該穿心蓮樣品可以為來爵床科(Acanthaceae)穿心蓮屬( Andrographis)的植物[即,穿心蓮( Andrographis paniculata)],較佳可以為前述植物的全株。舉例而言,該迷迭香萃取物可以藉由包含以下步驟之方法所製得:一樣品提供次步驟S21、一萃取次步驟S22、一濃縮次步驟S23,該穿心蓮萃取物則可以藉由包含以下步驟之方法所製得:一樣品提供次步驟S31、一萃取次步驟S32、一濃縮次步驟S33。 Furthermore, in the rosemary extract preparation step S2 and the Andrographis paniculata extract preparation step S3, the workers extracted a rosemary sample and an Andrographis paniculata sample with the extractant respectively. The rosemary sample can be a plant of the genus Rosmarinus (Lamiaceae) [i.e., rosemary ( Rosmarinus officinalis )], preferably the whole plant of the aforementioned plant, and the Andrographis paniculata sample can be For a plant of the genus Andrographis in the family Acanthaceae (ie, Andrographis paniculata ), it is preferably the whole plant of the aforementioned plant. For example, the rosemary extract can be prepared by a method including the following steps: providing a sample in step S21, an extraction in step S22, and a concentration in step S23. The Andrographis paniculata extract can be prepared by including It is prepared by the following steps: providing a sample in step S31, extracting in step S32, and concentrating in step S33.
於該樣品提供次步驟S21(或該樣品提供次步驟S31)中,工者係可以在取得該迷迭香樣品(或該穿心蓮樣品)之後直接進行該萃取次步驟S22,或者亦可以如前所述,在進行該萃取次步驟S22之前,預先進行乾燥或預先進行粉碎,使該迷迭香樣品(或該穿心蓮樣品)的含水量降低至3~10%,或使該迷迭香樣品(或該穿心蓮樣品)的粒徑可以介於5~20 nm之間。In the sample providing sub-step S21 (or the sample providing sub-step S31), the worker may directly perform the extraction sub-step S22 after obtaining the rosemary sample (or the Andrographis paniculata sample), or may also perform the extraction sub-step S22 as described above. As described above, before performing the extraction sub-step S22, dry or pulverize in advance to reduce the water content of the rosemary sample (or the Andrographis paniculata sample) to 3-10%, or make the rosemary sample (or The particle size of the Andrographis paniculata sample) can be between 5 and 20 nm.
於該萃取次步驟S22(或該萃取次步驟S32)中,工者係能夠以該磷酸鹽緩衝生理鹽水溶液作為萃取劑,以萃取該迷迭香樣品(或該穿心蓮樣品)。該磷酸鹽緩衝生理鹽水溶液可以為與該草珊瑚萃取物製備步驟S1的萃取次步驟S12中的配方相同者,惟工者亦可以依據該迷迭香樣品(或該穿心蓮樣品)與該草珊瑚樣品的狀態差異而自行調整,此為本發明所屬技術領域中具有通常知識者可以理解,於此不加以贅述。In the extraction sub-step S22 (or the extraction sub-step S32), the worker can use the phosphate buffered saline solution as an extraction agent to extract the rosemary sample (or the Andrographis paniculata sample). The phosphate buffered physiological saline solution can be the same as the formula in the extraction sub-step S12 of the grass coral extract preparation step S1. The craftsman can also use the rosemary sample (or the Andrographis paniculata sample) and the grass coral. Self-adjustment due to differences in the state of the sample is understandable to those with ordinary knowledge in the technical field to which the present invention belongs, and will not be described in detail here.
於本實施例中,每100克的迷迭香樣品(或穿心蓮樣品)係能夠混合200毫升的該萃取劑,以得一混合物,接著於與該草珊瑚萃取物製備步驟S1的萃取次步驟S12中所述的壓力、溫度範圍下進行萃取,萃取的時間亦可以與該草珊瑚萃取物製備步驟S1的萃取次步驟S12大致相同,以獲得一迷迭香粗萃液(或一穿心蓮粗萃液)。In this embodiment, every 100 grams of rosemary sample (or Andrographis paniculata sample) can be mixed with 200 ml of the extraction agent to obtain a mixture, and then in the extraction sub-step S12 of the grass coral extract preparation step S1 Extraction is carried out under the pressure and temperature range described in, and the extraction time can also be roughly the same as the extraction sub-step S12 of the grass coral extract preparation step S1, to obtain a rosemary crude extract (or an Andrographis paniculata crude extract). ).
於該濃縮次步驟S23(或該濃縮次步驟S33)中,工者係可以在取得該迷迭香粗萃液(或該穿心蓮粗萃液)之後,將該迷迭香粗萃液(或該穿心蓮粗萃液)進行冷凍乾燥,以獲得該迷迭香萃取物(或該穿心蓮萃取物),例如能夠係使用高速離心機,以12,000 rpm的轉速離心20分鐘,使該迷迭香粗萃液(或該穿心蓮粗萃液)中的殘渣沉澱之後,去除該些殘渣,續於介於-50~-80℃之間的溫度下,將所得的上清液冷凍乾燥以獲得乾燥粉體,即可以獲得該迷迭香萃取物(或該穿心蓮萃取物)。In the concentration sub-step S23 (or the concentration sub-step S33), the worker can, after obtaining the rosemary crude extract (or the Andrographis paniculata crude extract), add the rosemary crude extract (or the Andrographis paniculata crude extract). Andrographis paniculata crude extract) is freeze-dried to obtain the rosemary extract (or the Andrographis paniculata extract). For example, a high-speed centrifuge can be used to centrifuge at 12,000 rpm for 20 minutes to obtain the rosemary crude extract. After the residues in (or the Andrographis paniculata crude extract) are precipitated, the residues are removed, and then the resulting supernatant is freeze-dried at a temperature between -50 and -80°C to obtain a dry powder, i.e. This rosemary extract (or this andrographis paniculata extract) is available.
最後,於該調製步驟S4中,工者係可以依據所需比例,混合如前述之草珊瑚萃取物、迷迭香萃取物及穿心蓮萃取物,即可以得到該美白組合物。舉例而言,該美白組合物可以包含以重量百分比計為15~55%的草珊瑚萃取物、30~55%的迷迭香萃取物及15~55%的穿心蓮萃取物,較佳可以包含以重量百分比計為33.3%的草珊瑚萃取物、50%的迷迭香萃取物及16.7%的穿心蓮萃取物。Finally, in the preparation step S4, the worker can mix the aforementioned grass coral extract, rosemary extract and andrographis paniculata extract according to the required ratio to obtain the whitening composition. For example, the whitening composition may include 15% to 55% of Coral grass extract, 30% to 55% of rosemary extract, and 15% to 55% of Andrographis paniculata extract by weight. Preferably, it may include: The weight percentages are 33.3% Herba Coral extract, 50% Rosemary extract and 16.7% Andrographis paniculata extract.
值得注意的是,儘管工者可以依循如第1圖所示的用以製造獲得該美白組合物的方法,在分別藉由該草珊瑚萃取物製備步驟S1、該迷迭香萃取物製備步驟S2及該穿心蓮萃取物製備步驟S3,以分別製備該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物之後,續再藉由該調製步驟S4進而獲得該美白組合物。惟在所使用的各種參數大致相同的情況下,工者亦可以先混合該草珊瑚樣品、該迷迭香樣品及該穿心蓮樣品,再以該萃取劑萃取包含該草珊瑚樣品、該迷迭香樣品及該穿心蓮樣品的一混合樣品(例如,當預計獲得包含以重量百分比計為33.3%的草珊瑚萃取物、50%的迷迭香萃取物及16.7%的穿心蓮萃取物的美白組合物時,該混合樣品可以包含以重量百分比計為33.3%的草珊瑚樣品、50%的迷迭香樣品及16.7%的穿心蓮樣品),續進行濃縮亦可以獲得該美白組合物,如此可以提升製備該美白組合物的便利性,進而降低該美白組合物的製備成本。It is worth noting that although workers can follow the method for manufacturing the whitening composition as shown in Figure 1, in the preparation step S1 of the grass coral extract and the preparation step S2 of the rosemary extract respectively And the Andrographis paniculata extract preparation step S3 is to respectively prepare the grass coral extract, the rosemary extract and the Andrographis paniculata extract, and then continue to obtain the whitening composition through the preparation step S4. However, when the various parameters used are roughly the same, workers can also first mix the grass coral sample, the rosemary sample and the andrographis paniculata sample, and then use the extractant to extract the grass coral sample, the rosemary sample sample and a mixed sample of the Andrographis paniculata sample (for example, when it is expected to obtain a whitening composition containing 33.3% Herba Coral extract, 50% Rosemary extract and 16.7% Andrographis paniculata extract by weight percentage, The mixed sample may include 33.3% of the grass coral sample, 50% of the rosemary sample and 16.7% of the Andrographis paniculata sample by weight), and the whitening composition can also be obtained by continuing to concentrate, which can improve the preparation of the whitening composition. The convenience of the product thereby reduces the preparation cost of the whitening composition.
本發明之美白組合物,係可以抑制黑色素細胞中的酪胺酸酶的表現量及活性,進而降低黑色素細胞中的黑色素含量,因而可以應用於製備美白製劑,該美白組合物可以與至少一醫藥學上可接受之載體共同組成該美白製劑,或是於該美白製劑中額外添加他種降低黑色素細胞中的黑色素含量之活性成分,以共同投予一所需個體(例如能夠以200~500 μg/cm 2的劑量施予於該所需個體的皮膚上),該載體係為一賦型劑或一添加劑,較佳係可以共同形成液狀、乳液狀、乳霜狀或膠狀等各種型態之製劑,進而能夠便於該所需個體的使用。 The whitening composition of the present invention can inhibit the expression and activity of tyrosinase in melanocytes, thereby reducing the melanin content in melanocytes. Therefore, it can be used to prepare whitening preparations. The whitening composition can be combined with at least one medicine. A scientifically acceptable carrier is used to form the whitening preparation, or other active ingredients that reduce the melanin content in melanocytes are additionally added to the whitening preparation to be co-administered to a desired individual (for example, 200 to 500 μg can be used) /cm 2 is applied to the skin of the desired individual), the carrier system is an excipient or an additive, preferably it can jointly form various types such as liquid, emulsion, cream or gel. The preparation is in a state that can be easily used by the desired individual.
為了證實本發明的美白組合物可以有效抑制酪胺酸酶的活性,遂進行以下試驗:In order to confirm that the whitening composition of the present invention can effectively inhibit the activity of tyrosinase, the following tests were conducted:
(A)酪胺酸酶抑制試驗(I)(A) Tyrosinase inhibition test (I)
本試驗係依據如第1表所示的重量百分比混合該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物,以獲得如第A6~A8組的美白組合物(該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物的濃度總和均為150 μg/mL);另以濃度為150 μg/mL的草珊瑚萃取物、迷迭香萃取物及穿心蓮萃取物分別作為第A3~A5組的待測樣品。又,本試驗的第A0組係為空白組,即未加入任一萃取物及維他命C的組別(僅加入酪胺酸酶及含多巴的基質液),第A1組係為負控制組,即僅有含多巴的基質液的組別,第A2組則為正控制組,未加入任一萃取物,但加入維他命C(40 μg/mL)、酪胺酸酶及含多巴的基質液。This test is based on mixing the grass coral extract, the rosemary extract and the Andrographis paniculata extract according to the weight percentages shown in Table 1 to obtain whitening compositions of groups A6 to A8 (the grass coral extract , the total concentration of the rosemary extract and the Andrographis paniculata extract is 150 μg/mL); in addition, the grass coral extract, rosemary extract and Andrographis paniculata extract with a concentration of 150 μg/mL are respectively used as A3 ~Samples to be tested in group A5. In addition, Group A0 of this test is the blank group, that is, the group in which no extract and vitamin C are added (only tyrosinase and dopa-containing matrix solution are added), and Group A1 is the negative control group. , that is, the group with only dopa-containing matrix fluid. Group A2 is the positive control group. No extract is added, but vitamin C (40 μg/mL), tyrosinase and dopa-containing solution are added. matrix fluid.
第1表、本試驗各組的待測樣品。
將如前述的待測樣品(60 μL)混合酪胺酸酶(3 μL),於反應5分鐘之後,再加入基質液(多巴 10 mM;540 μL),於37℃的溫度下反應20分鐘,使酪胺酸酶將該基質液中的多巴轉化為多巴醌。最後,測量各組反應液於450 nm的波長下的吸光值,以如下的式一計算各組反應液的相對吸光值,即可以換算得知各組待測樣品的相對酪胺酸酶活性。 (式一) Mix the sample to be tested (60 μL) as described above with tyrosinase (3 μL). After reacting for 5 minutes, add matrix solution (DOPA 10 mM; 540 μL) and react at 37°C for 20 minutes. , allowing tyrosinase to convert dopa in the matrix solution into dopaquinone. Finally, measure the absorbance value of each group of reaction solutions at a wavelength of 450 nm, and calculate the relative absorbance value of each group of reaction solutions using the following formula 1, which can be converted to obtain the relative tyrosinase activity of each group of samples to be tested. (Formula 1)
請參照第1表及第2圖所示,單獨加入該草珊瑚萃取物、該迷迭香萃取物或該穿心蓮萃取物均可以有效抑制酪胺酸酶的活性(第A3~A5組;*: P<0.05,與第A0組相比),且加入包含該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物的美白組合物亦可以有效抑制酪胺酸酶的活性(第A6~A8組;*: P<0.05,與第A0組相比)。 Please refer to Table 1 and Figure 2. Adding alone the grass coral extract, the rosemary extract or the Andrographis paniculata extract can effectively inhibit the activity of tyrosinase (Groups A3 to A5; *: P < 0.05, compared with group A0), and adding the whitening composition containing the grass coral extract, the rosemary extract and the andrographis paniculata extract can also effectively inhibit the activity of tyrosinase (group A6~ Group A8; *: P <0.05, compared with group A0).
值得注意的是,再請參照第1表及第2圖所示,與分別單獨加入該草珊瑚萃取物、該迷迭香萃取物或該穿心蓮萃取物的第A3~A5組相比,加入包含該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物的美白組合物更可以有效抑制酪胺酸酶的活性(第A6~A8組;@: P<0.05,與第A3組相比;$: P<0.05,與第A4組相比;%: P<0.05,與第A5組相比),顯示該美白組合物藉由該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物的共同作用,具有較佳的酪胺酸酶的抑制活性。 It is worth noting that, please refer to Table 1 and Figure 2 again, compared with groups A3 to A5 in which the grass coral extract, the rosemary extract or the Andrographis paniculata extract were added separately, the addition of The whitening composition of the grass coral extract, the rosemary extract and the Andrographis paniculata extract can more effectively inhibit the activity of tyrosinase (groups A6 to A8; @: P <0.05, compared with group A3 ; $: P < 0.05, compared with group A4; %: P < 0.05, compared with group A5), showing that the whitening composition uses the grass coral extract, the rosemary extract and the andrographis paniculata The combined effect of the extracts has better tyrosinase inhibitory activity.
特別需要說明的是,另請參照第1表及第2圖所示,與同樣加入包含該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物的美白組合物的第A6、A8組相比,加入包含以重量百分比計為33.3%的草珊瑚萃取物、50.0%的迷迭香萃取物及16.7%的穿心蓮萃取物的美白組合物的第A7組更可以有效抑制酪胺酸酶的活性(第A6、A8組;&: P<0.05,與第A7組相比),顯示包含前述特定比例的美白組合物藉由該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物的特定比例,具有較佳的酪胺酸酶的抑制活性,故後續試驗均係以前述特定比例的美白組合物進行。 In particular, please refer to Table 1 and Figure 2, which are groups A6 and A8 that also add the whitening composition containing the grass coral extract, the rosemary extract and the Andrographis paniculata extract. In comparison, Group A7, which added a whitening composition containing 33.3% of Coral grass extract, 50.0% of Rosemary extract and 16.7% of Andrographis paniculata extract by weight, was more effective in inhibiting tyrosinase. Activity (Groups A6, A8; &: P < 0.05, compared with Group A7), showing that the whitening composition containing the aforementioned specific ratio is composed of the grass coral extract, the rosemary extract and the Andrographis paniculata extract. The specific ratio has better tyrosinase inhibitory activity, so subsequent tests were conducted using the whitening composition in the specific ratio mentioned above.
(B)酪胺酸酶抑制試驗(II)(B) Tyrosinase inhibition test (II)
請參照第2表所示,本試驗第B3~B5組的美白組合物係同樣包含以重量百分比計為33.3%的草珊瑚萃取物、50.0%的迷迭香萃取物及16.7%的穿心蓮萃取物,惟需要注意的是,第B3組的美白組合物中的草珊瑚萃取物、迷迭香萃取物及穿心蓮萃取物均係以95%的乙醇水溶液作為萃取劑所萃取獲得;第B4組的美白組合物中的草珊瑚萃取物、迷迭香萃取物及穿心蓮萃取物均係以99.9%的甲醇水溶液作為萃取劑所萃取獲得;而第B5組的美白組合物中的草珊瑚萃取物、迷迭香萃取物及穿心蓮萃取物則均以該磷酸鹽緩衝生理鹽水溶液作為萃取劑所萃取獲得。又,本試驗的第B0組係為如前述之空白組,第B1組係為如前述之負控制組,且第B2組則為如前述之正控制組,並以如下的式二計算各組反應液的相對吸光值,即可以換算得知各組待測樣品的相對酪胺酸酶活性。 (式二) Please refer to Table 2. The whitening compositions of Groups B3 to B5 of this trial also include 33.3% by weight of grass coral extract, 50.0% of rosemary extract and 16.7% of Andrographis paniculata extract. , but it should be noted that the grass coral extract, rosemary extract and Andrographis paniculata extract in the whitening composition of Group B3 are all extracted using 95% ethanol aqueous solution as the extraction agent; the whitening composition of Group B4 The grass coral extract, rosemary extract and andrographis paniculata extract in the composition are all extracted using 99.9% methanol aqueous solution as the extraction agent; and the grass coral extract, rosemary extract in the whitening composition of Group B5 Both the aromatic extract and the Andrographis paniculata extract were extracted using the phosphate buffered saline solution as the extraction agent. In addition, Group B0 of this experiment is the blank group as mentioned above, Group B1 is the negative control group as mentioned above, and Group B2 is the positive control group as mentioned above, and each group is calculated according to the following formula 2 The relative absorbance value of the reaction solution can be converted into the relative tyrosinase activity of each group of samples to be tested. (Formula 2)
第2表、本試驗各組的待測樣品。
請參照第2表及第3圖所示,與以95%的乙醇水溶液作為萃取劑所萃取獲得的第B3組美白組合物,或與以99.9%的甲醇水溶液作為萃取劑所萃取獲得的第B4組美白組合物相比,以該磷酸鹽緩衝生理鹽水溶液作為萃取劑所萃取獲得的第B5組美白組合物更可以有效抑制酪胺酸酶的活性(第B3、B4組;$: P<0.05,與第B5組相比),顯示該美白組合物藉由以該磷酸鹽緩衝生理鹽水溶液作為萃取劑,可以較容易自該草珊瑚樣品、該迷迭香樣品及該穿心蓮樣品中萃取出具有酪胺酸酶抑制活性的有效成分。 Please refer to Table 2 and Figure 3 for the whitening composition of Group B3 extracted with 95% ethanol aqueous solution as the extractant, or with the B4 whitening composition extracted with 99.9% methanol aqueous solution as the extractant. Compared with the whitening compositions of Group B5, the whitening compositions of Group B5 extracted using the phosphate buffered saline solution as the extraction agent can more effectively inhibit the activity of tyrosinase (Groups B3 and B4; $: P <0.05 , compared with Group B5), showing that the whitening composition can more easily extract the properties from the grass coral sample, the rosemary sample and the Andrographis paniculata sample by using the phosphate buffered saline solution as the extraction agent. Active ingredient with tyrosinase inhibitory activity.
(C)黑色素含量測定(C)Melanin content measurement
請參照第3表所示,本試驗第C3組的美白組合物係包含以重量百分比計為33.3%的草珊瑚萃取物、50.0%的迷迭香萃取物及16.7%的穿心蓮萃取物,且該美白組合物中的草珊瑚萃取物、迷迭香萃取物及穿心蓮萃取物則均以該磷酸鹽緩衝生理鹽水溶液作為萃取劑所萃取獲得。又,本試驗的第C0組係為如前述之空白組,第C1組係為如前述之負控制組,且第C2組則為如前述之正控制組。Please refer to Table 3. The whitening composition of Group C3 of this trial contains 33.3% Coral grass extract, 50.0% Rosemary extract and 16.7% Andrographis paniculata extract by weight percentage, and the The grass coral extract, rosemary extract and Andrographis paniculata extract in the whitening composition are all extracted using the phosphate buffered physiological saline solution as the extraction agent. In addition, the C0 group of this experiment is the blank group as mentioned above, the C1 group is the negative control group as mentioned above, and the C2 group is the positive control group as mentioned above.
第3表、本試驗各組的待測樣品。
本試驗係以小鼠黑色素瘤B16-F10細胞作為模式細胞株,將如第3表所示的待測樣品加入該模式細胞株中,並於反應24小時之後,收集該模式細胞株。接著,於所收集的模式細胞株中加入氫氧化鈉(sodium hydroxide,NaOH)水溶液(1 N,0.2 mL),於80℃的溫度下反應2小時,使該模式細胞株中的黑色素溶出之後,以12,000 rpm的轉速離心30分鐘並收集上清液,續測量各組上清液於405 nm的波長下的吸光值,以如下的式三計算各組上清液的相對吸光值,即可以換算得知各組待測樣品的相對黑色素含量。 (式三) This test uses mouse melanoma B16-F10 cells as a model cell line. The test samples shown in Table 3 are added to the model cell line, and the model cell line is collected after 24 hours of reaction. Next, add sodium hydroxide (NaOH) aqueous solution (1 N, 0.2 mL) to the collected model cell line, and react at 80°C for 2 hours to dissolve the melanin in the model cell line. Centrifuge at 12,000 rpm for 30 minutes and collect the supernatant. Continue to measure the absorbance value of the supernatant in each group at a wavelength of 405 nm. Use the following formula 3 to calculate the relative absorbance value of the supernatant in each group, which can be converted. Know the relative melanin content of each group of samples to be tested. (Formula 3)
請參照第3表及第4圖所示,以該磷酸鹽緩衝生理鹽水溶液作為萃取劑所萃取獲得的第C3組美白組合物可以有效降低黑色素細胞中的黑色素含量,且效果與正控制組的維他命C相仿。Please refer to Table 3 and Figure 4. The C3 whitening composition extracted using the phosphate buffered saline solution as the extraction agent can effectively reduce the melanin content in melanocytes, and the effect is the same as that of the positive control group. Vitamin C is similar.
(D)對黑色素合成相關的訊息傳遞路徑的影響(D) Effect on message transmission pathways related to melanin synthesis
請參照第4表所示,本試驗第D1組的美白組合物係包含以重量百分比計為33.3%的草珊瑚萃取物、50.0%的迷迭香萃取物及16.7%的穿心蓮萃取物,且該美白組合物中的草珊瑚萃取物、迷迭香萃取物及穿心蓮萃取物則均以該磷酸鹽緩衝生理鹽水溶液作為萃取劑所萃取獲得。又,本試驗的第D0組係為如前述之空白組。Please refer to Table 4. The whitening composition of Group D1 of this trial contains 33.3% of Coral grass extract, 50.0% of Rosemary extract and 16.7% of Andrographis paniculata extract by weight, and the The grass coral extract, rosemary extract and Andrographis paniculata extract in the whitening composition are all extracted using the phosphate buffered physiological saline solution as the extraction agent. In addition, the D0 group in this test is the blank group as mentioned above.
第4表、本試驗各組的待測樣品。
本試驗同樣以小鼠黑色素瘤B16-F10細胞作為模式細胞株,將如第4表所示的待測樣品加入該模式細胞株中,並於反應24小時之後,收集該模式細胞株。接著,在裂解該模式細胞株之後,以12,000 rpm的轉速離心30分鐘並收集上清液,續將各組上清液在定量之後,以十二烷基硫酸鈉聚丙烯醯胺凝膠電泳(sodium dodecyl sulfate polyacrylamide gel electrophoresis,簡稱為SDS-PAGE)進行分析,接著將十二烷基硫酸鈉聚丙烯醯胺凝膠上的蛋白質轉印至聚偏二氟乙烯膜(polyvinylidene difluoride,簡稱為PVDF)上,再使用針對黑素皮質素受體1(melanocortin 1 receptor,簡稱為MC1R)、酪胺酸酶(tyrosinase)、酪胺酸酶相關蛋白1(tyrosinase-related protein 1,簡稱為TRP1)及多巴色素互變異構酶(dopachrome tautomerase,簡稱為DCT)的抗體,偵測各組上清液中的各蛋白質的含量,並以β-肌動蛋白(β-actin)的蛋白質含量作為內控制組(internal control),換算為個蛋白質相對於β-肌動蛋白(β-actin)的相對蛋白質含量。其中,黑素皮質素受體1(MC1R)在與α-黑色素細胞刺激素(α-melanocyte-stimulating hormone,簡稱為α-MSH)結合之後會導致細胞內的環腺苷酸(cyclic adenosine monophosphate,簡稱為cAMP)的含量提升,進而促進酪胺酸酶(tyrosinase)、酪胺酸酶相關蛋白1(TRP1)及多巴色素互變異構酶(DCT)等蛋白質的表現,酪胺酸酶可以將黑色素細胞中的多巴(DOPA)氧化形成多巴醌(dopaquinone),進而形成多巴色素(dopachrome),最終轉化為真黑色素(eumelanin);而多巴色素(dopachrome)在經過多巴色素互變異構酶(DCT)的作用可以形成5,6-二羥基吲哚-2-羧酸(5,6-dihydroxyindole-2-carboxylic acid,簡稱為DHICA)之後再形成真黑色素(eumelanin),5,6-二羥基吲哚-2-羧酸(DHICA)亦可以藉由酪胺酸酶相關蛋白1(TRP1)的作用而形成真黑色素(eumelanin),換言之,黑素皮質素受體1(MC1R)、酪胺酸酶(tyrosinase)、酪胺酸酶相關蛋白1(TRP1)及多巴色素互變異構酶(DCT)均為促進黑色素生成的訊息傳遞路徑上的重要蛋白質。This experiment also uses mouse melanoma B16-F10 cells as the model cell line. The test samples shown in Table 4 are added to the model cell line, and the model cell line is collected after 24 hours of reaction. Next, after lysing the model cell line, centrifuge at 12,000 rpm for 30 minutes and collect the supernatant. After quantification, the supernatant of each group was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis ( sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE for short) was analyzed, and then the proteins on the sodium dodecyl sulfate polyacrylamide gel were transferred to polyvinylidene difluoride (PVDF for short) on, and then use drugs targeting melanocortin 1 receptor (MC1R), tyrosinase, tyrosinase-related protein 1 (TRP1) and more Antibodies against dopachrome tautomerase (DCT) were used to detect the protein content in the supernatants of each group, and the protein content of β-actin (β-actin) was used as the internal control group. (internal control), converted into the relative protein content of a protein relative to β-actin (β-actin). Among them, melanocortin receptor 1 (MC1R), after binding to α-melanocyte-stimulating hormone (α-MSH), causes intracellular cyclic adenosine monophosphate, The content of cAMP for short increases, thereby promoting the expression of proteins such as tyrosinase (tyrosinase), tyrosinase-related protein 1 (TRP1) and dopachrome tautomerase (DCT). Tyrosinase can convert DOPA in melanocytes is oxidized to form dopaquinone, which then forms dopachrome, and is finally converted into eumelanin; dopachrome undergoes intermutation of dopachrome The action of DCT can form 5,6-dihydroxyindole-2-carboxylic acid (DHICA) and then eumelanin, 5,6 -Dihydroxyindole-2-carboxylic acid (DHICA) can also form eumelanin through the action of tyrosinase-related protein 1 (TRP1), in other words, melanocortin receptor 1 (MC1R), Tyrosinase, tyrosinase-related protein 1 (TRP1) and dopachrome tautomerase (DCT) are important proteins in the message transmission pathway that promotes melanin production.
請參照第4表及第5圖所示,於第D1組中,無論是黑素皮質素受體1(MC1R)、酪胺酸酶(tyrosinase)、酪胺酸酶相關蛋白1(TRP1)及多巴色素互變異構酶(DCT)的相對蛋白質含量均具有顯著的降低,可以證實該美白組合物確實能夠阻斷促進黑色素生成的訊息傳遞路徑,進而有效降低黑色素的生成。Please refer to Table 4 and Figure 5. In group D1, whether it is melanocortin receptor 1 (MC1R), tyrosinase (tyrosinase), tyrosinase-related protein 1 (TRP1) and The relative protein content of dopachrome tautomerase (DCT) has been significantly reduced, which can confirm that the whitening composition can indeed block the message transmission pathway that promotes melanin production, thereby effectively reducing melanin production.
綜上所述,本發明的美白組合物,藉由該草珊瑚萃取物、該迷迭香萃取物及該穿心蓮萃取物的組成,不僅可以有效抑制酪胺酸酶的活性,更可以阻斷與黑色素生成有關的訊息傳遞路徑,進而能夠減少黑色素的生成,因此,該美白組合物可以應用於製備美白製劑,供投予一所需個體,以抑制該所需個體的黑色素細胞中的黑色素的生成,為本發明之功效。In summary, the whitening composition of the present invention, composed of the grass coral extract, the rosemary extract and the Andrographis paniculata extract, can not only effectively inhibit the activity of tyrosinase, but also block the activity of tyrosinase. The message transmission pathway related to melanin production can thereby reduce the production of melanin. Therefore, the whitening composition can be used to prepare a whitening preparation for administration to a desired individual to inhibit the production of melanin in the melanocytes of the desired individual. , which is the effect of the present invention.
再且,本發明的美白組合物的用途,藉由使用如前述的美白組合物,進而能夠達成有效抑制黑色素的生成之功效。Furthermore, the use of the whitening composition of the present invention can further achieve the effect of effectively inhibiting the production of melanin by using the aforementioned whitening composition.
雖然本發明已利用上述較佳實施例揭示,然其並非用以限定本發明,任何熟習此技藝者在不脫離本發明之精神和範圍之內,相對上述實施例進行各種更動與修改仍屬本發明所保護之技術範疇,因此本發明之保護範圍當包含後附之申請專利範圍所記載的文義及均等範圍內之所有變更。Although the present invention has been disclosed using the above-mentioned preferred embodiments, they are not intended to limit the invention. Anyone skilled in the art can make various changes and modifications to the above-described embodiments without departing from the spirit and scope of the invention. The technical scope protected by the invention, therefore, the protection scope of the invention shall include all changes within the literal and equivalent scope described in the appended patent application scope.
﹝本發明﹞ S1:草珊瑚萃取物製備步驟 S11:樣品提供次步驟 S12:萃取次步驟 S13:濃縮次步驟 S2:迷迭香萃取物製備步驟 S21:樣品提供次步驟 S22:萃取次步驟 S23:濃縮次步驟 S3:穿心蓮萃取物製備步驟 S31:樣品提供次步驟 S32:萃取次步驟 S33:濃縮次步驟 S4:調製步驟﹝This invention﹞ S1: Preparation steps of grass coral extract S11: Sample provision sub-step S12: Extraction sub-step S13: Concentration sub-step S2: Rosemary extract preparation steps S21: Sample provision sub-step S22: Extraction sub-step S23: Concentration sub-step S3: Preparation steps of Andrographis paniculata extract S31: Sample provision sub-step S32: Extraction sub-step S33: Concentration sub-step S4: Modulation step
[第1圖] 用以製造本發明之一實施例的美白組合物的方法的流程圖。 [第2圖] 試驗(A)中,第A0~A8組待測樣品的相對酪胺酸酶活性的柱狀圖(*: P<0.05,與第A0組相比;#: P<0.01,與第A2組相比;@: P<0.05,與第A3組相比;$: P<0.05,與第A4組相比;%: P<0.05,與第A5組相比;&: P<0.05,與第A7組相比)。 [第3圖] 試驗(B)中,第B0~B5組待測樣品的相對酪胺酸酶活性的柱狀圖(*: P<0.05,與第B0組相比;#: P<0.01,與第B2組相比;$: P<0.05,與第B5組相比)。 [第4圖] 試驗(C)中,第C0~C3組待測樣品的相對細胞內黑色素含量柱狀圖。 [第5圖] 試驗(D)中,第D0~D1組待測樣品的相對蛋白質含量柱狀圖。 [Figure 1] A flow chart of a method for manufacturing a whitening composition according to an embodiment of the present invention. [Picture 2] In test (A), the histogram of the relative tyrosinase activity of the samples to be tested in groups A0 to A8 (*: P <0.05, compared with group A0; #: P <0.01, Compared with group A2; @: P <0.05, compared with group A3; $: P <0.05, compared with group A4; %: P <0.05, compared with group A5; &: P < 0.05, compared with group A7). [Figure 3] In test (B), the bar graph of the relative tyrosinase activity of the samples to be tested in groups B0 to B5 (*: P <0.05, compared with group B0; #: P <0.01, Compared with group B2; $: P <0.05, compared with group B5). [Picture 4] In the test (C), the histogram of the relative intracellular melanin content of the samples to be tested in groups C0 to C3. [Figure 5] In test (D), the relative protein content histogram of the samples to be tested in groups D0 to D1.
S1:草珊瑚萃取物製備步驟 S1: Preparation steps of grass coral extract
S11:樣品提供次步驟 S11: Sample provision sub-step
S12:萃取次步驟 S12: Extraction sub-step
S13:濃縮次步驟 S13: Concentration sub-step
S2:迷迭香萃取物製備步驟 S2: Rosemary extract preparation steps
S21:樣品提供次步驟 S21: Sample provision sub-step
S22:萃取次步驟 S22: Extraction sub-step
S23:濃縮次步驟 S23: Concentration sub-step
S3:穿心蓮萃取物製備步驟 S3: Preparation steps of Andrographis paniculata extract
S31:樣品提供次步驟 S31: Sample provision sub-step
S32:萃取次步驟 S32: Extraction sub-step
S33:濃縮次步驟 S33: Concentration sub-step
S4:調製步驟 S4: Modulation step
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW112104281A TWI826254B (en) | 2023-02-07 | 2023-02-07 | Whitening composition and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW112104281A TWI826254B (en) | 2023-02-07 | 2023-02-07 | Whitening composition and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI826254B true TWI826254B (en) | 2023-12-11 |
Family
ID=90053378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW112104281A TWI826254B (en) | 2023-02-07 | 2023-02-07 | Whitening composition and use thereof |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI826254B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101721334A (en) * | 2008-11-03 | 2010-06-09 | 杨来香 | Sunscreen cream containing sarcandra glabra fluid extract |
CN108478607A (en) * | 2018-04-26 | 2018-09-04 | 广西呈鸣生物科技有限公司 | A kind of preparation method of Herba Pileae Scriptae extract liposome hydrogel |
-
2023
- 2023-02-07 TW TW112104281A patent/TWI826254B/en active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101721334A (en) * | 2008-11-03 | 2010-06-09 | 杨来香 | Sunscreen cream containing sarcandra glabra fluid extract |
CN108478607A (en) * | 2018-04-26 | 2018-09-04 | 广西呈鸣生物科技有限公司 | A kind of preparation method of Herba Pileae Scriptae extract liposome hydrogel |
Non-Patent Citations (2)
Title |
---|
期刊 Ping-Ya Zhu Andrographolide suppresses melanin synthesis through Akt/GSK3b/b-catenin signal pathway Journal of Dermatological Science 2015 2015 1-10 * |
期刊 刘玉荣 迷迭香精油对黑色素细胞抗氧化特性及黑色素生成的影响 长治医学院学报 第5期/35卷 2021年10月 327-329; * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5538611B2 (en) | Maillard reaction inhibitor | |
EP3533454B1 (en) | Composition comprising a mixture of plant extracts or a mixture of molecules contained in said plants and use to act on the carbohydrate and/or lipid metabolism | |
FR2779058A1 (en) | USE OF AT LEAST ONE COSMETICALLY ACCEPTABLE SAPONIN OR SAPOGENOL AS A COSMETIC AGENT FOR INCREASING THE QUANTITY OF COLLAGEN IV IN THE DERMO-EPIDERMAL JUNCTION | |
JP2014028814A (en) | Deglycation of age | |
WO1999016415A1 (en) | Use of ellagic acid and its derivatives in cosmetics and dermatology | |
KR20070087552A (en) | Skin whitening preparation for external use, whitening preparation, whitening method and method of producing skin whitening preparation for external use | |
WO2021017910A1 (en) | External skin treatment composition with enhanced anti-inflammatory effect | |
CN106794136B (en) | Deglycosylation of a combination of salvia miltiorrhiza extract and niacin and/or niacinamide | |
KR20140040184A (en) | Pharmaceutical, cosmetic, and functional food compositions comprising smilacis chinae rhizoma of smilax china l. for allergic diseases | |
AU2004216521B2 (en) | Method for the production of flavonoid-containing compositions and use thereof | |
JP3502415B2 (en) | Maillard reaction inhibitor | |
JPH08325156A (en) | Skin preparation for external use, drink and food product containing steviol glycoside | |
JP2004067590A (en) | Female sex hormone production promoter and skin preparation for external use containing the same | |
TWI826254B (en) | Whitening composition and use thereof | |
JP2006062989A (en) | Elastase activity inhibitor or maillard reaction suppressant | |
JP2011195532A (en) | Protein glycation inhibitor | |
JP2008247779A (en) | Antiallergic food and antiallergic external preparation | |
JP2007261996A (en) | Acrolein adduct-forming inhibitor, and skin external preparation and food and drink containing the same | |
JP4866012B2 (en) | Acrolein adduct formation inhibitor, skin external preparation and health supplement containing the same | |
JP2011195530A (en) | Protein glycation inhibitor | |
FR2941864A1 (en) | ACTIVE SUBSTANCE FOR THE PROTECTION OF FGF-2 | |
US9925134B2 (en) | Use of substances to protect FGF-2 or FGF-beta growth factor | |
Panda et al. | Antioxidant and cardioprotective effects of Garcinia indica (kokoberry), an Indian super fruit in isoproterenol induced myocardial necrosis in rats | |
KR102377167B1 (en) | manufacturing method of cosmetic composition containing extract of Hevea brasiliensis leafs | |
US20090304822A1 (en) | Extract of Polygonum multiflorum Thunb. ex Murray var. hypoleucum and compositions for improving metabolic syndrome |